Furmonertinib Evidence: Trial Results and Peer-Reviewed Publications

Carcinoma, Non-Small-Cell Lung (59)

• Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.
  Radiat Oncol · 2024 · PMID 39506792 · NCT07482605
• Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy.
  Front Oncol · 2024 · PMID 37274290 · NCT07482605
• Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
  Thorac Cancer · 2024 · PMID 38226415 · NCT07482605
• Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.
  JTO Clin Res Rep · 2024 · PMID 36438852 · NCT07482605
• Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
  Cancer Med · 2023 · PMID 37288833 · NCT07482605

2024 (4 papers)

1. Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.
   Li W, Wu P, Liang Z, et al. · Radiat Oncol · 2024 · Background
   PubMed: PMID 39506792 · NCT07482605 · Carcinoma, Non-Small-Cell Lung
2. Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy.
   Li Q, Hu C, Su S, et al. · Front Oncol · 2024 · Background
   PubMed: PMID 37274290 · NCT07482605 · Carcinoma, Non-Small-Cell Lung
3. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
   Kiritani A, Amino Y, Uchibori K, et al. · Thorac Cancer · 2024 · Background
   PubMed: PMID 38226415 · NCT07482605 · Carcinoma, Non-Small-Cell Lung
4. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.
   Hibino M, Hiranuma O, Takemura Y, et al. · JTO Clin Res Rep · 2024 · Background
   PubMed: PMID 36438852 · NCT07482605 · Carcinoma, Non-Small-Cell Lung

2023 (1 paper)

1. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
   Li Q, Hu C, Su S, et al. · Cancer Med · 2023 · Background
   PubMed: PMID 37288833 · NCT07482605 · Carcinoma, Non-Small-Cell Lung

2022 (3 papers)

1. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
   Zhou Q, Xu CR, Cheng Y, et al. · Cancer Cell · 2022 · Background
   PubMed: PMID 34388377 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
   Nokihara H, Ogino H, Mitsuhashi A, et al. · BMC Cancer · 2022 · Background
   PubMed: PMID 35650550 · NCT07482605 · Carcinoma, Non-Small-Cell Lung
3. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.
   Deng H, Liu J, Cai X, et al. · Ann Surg · 2022 · Background
   PubMed: PMID 34596079 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2021 (6 papers)

1. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
   Yang JC, Camidge DR, Yang CT, et al. · J Thorac Oncol · 2021 · Background
   PubMed: PMID 32916310 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
   Shi Y, Zhang S, Hu X, et al. · J Thorac Oncol · 2021 · Background
   PubMed: PMID 32007598 · NCT04970693 · Carcinoma, Non-Small-Cell Lung
3. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
   Shi Y, Hu X, Zhang S, et al. · Lancet Respir Med · 2021 · Background
   PubMed: PMID 33780662 · NCT04970693 · Carcinoma, Non-Small-Cell Lung
4. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
   Shah R, Lester JF · Clin Lung Cancer · 2021 · Background
   PubMed: PMID 32014348 · NCT04970693 · Carcinoma, Non-Small-Cell Lung
5. Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.
   Li K, Cao X, Ai B, et al. · Thorac Cancer · 2021 · Background
   PubMed: PMID 34128318 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
6. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
   Eide IJZ, Helland Å, Ekman S, et al. · Lung Cancer · 2021 · Background
   PubMed: PMID 32200138 · NCT04970693 · Carcinoma, Non-Small-Cell Lung

2020 (5 papers)

1. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
   Zhong WZ, Chen KN, Chen C, et al. · J Clin Oncol · 2020 · Background
   PubMed: PMID 31194613 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Cancer statistics, 2020.
   Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2020 · Background
   PubMed: PMID 31912902 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
3. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
   Schmid S, Klingbiel D, Aeppli S, et al. · Lung Cancer · 2020 · Background
   PubMed: PMID 30885336 · NCT04970693 · Carcinoma, Non-Small-Cell Lung
4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
   Ramalingam SS, Vansteenkiste J, Planchard D, et al. · N Engl J Med · 2020 · Background
   PubMed: PMID 31751012 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
5. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
   Mu Y, Hao X, Xing P, et al. · J Cancer Res Clin Oncol · 2020 · Background
   PubMed: PMID 32385709 · NCT04970693 · Carcinoma, Non-Small-Cell Lung

2019 (1 paper)

1. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
   Wu YL, Ahn MJ, Garassino MC, et al. · J Clin Oncol · 2019 · Background
   PubMed: PMID 30059262 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2018 (2 papers)

1. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
   Zhong WZ, Wang Q, Mao WM, et al. · Lancet Oncol · 2018 · Background
   PubMed: PMID 29174310 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
   Qiu B, Liang Y, Li Q, et al. · Clin Lung Cancer · 2018 · Background
   PubMed: PMID 28465010 · NCT04970693 · Carcinoma, Non-Small-Cell Lung

2017 (4 papers)

1. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
   Yang JC, Ahn MJ, Kim DW, et al. · J Clin Oncol · 2017 · Background
   PubMed: PMID 28221867 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
   Rami-Porta R, Asamura H, Travis WD, et al. · CA Cancer J Clin · 2017 · Background
   PubMed: PMID 28140453 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
3. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
   Goss G, Tsai CM, Shepherd FA, et al. · Lancet Oncol · 2017 · Background
   PubMed: PMID 27751847 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
4. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
   Gomez DR, Blumenschein GR, Lee JJ, et al. · Lancet Oncol · 2017 · Background
   PubMed: PMID 27789196 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2016 (5 papers)

1. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
   Zhou C, Wu YL, Chen G, et al. · Ann Oncol · 2016 · Background
   PubMed: PMID 26141208 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
   Goldstraw P, Chansky K, Crowley J, et al. · J Thorac Oncol · 2016 · Background
   PubMed: PMID 26762738 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
3. Comprehensive genomic profiles of small cell lung cancer.
   George J, Lim JS, Jang SJ, et al. · Nature · 2016 · Background
   PubMed: PMID 26168399 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
4. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
   Cross DA, Ashton SE, Ghiorghiu S, et al. · Cancer Discov · 2016 · Background
   PubMed: PMID 24893891 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
5. Cancer statistics in China, 2015.
   Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
   PubMed: PMID 26808342 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2015 (2 papers)

1. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
   Nakaoku T, Tsuta K, Ichikawa H, et al. · Clin Cancer Res · 2015 · Background
   PubMed: PMID 24727320 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
   Li N, Ou W, Ye X, et al. · Ann Surg Oncol · 2015 · Background
   PubMed: PMID 24585406 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2014 (4 papers)

1. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
   NSCLC Meta-analysis Collaborative Group · Lancet · 2014 · Background
   PubMed: PMID 24576776 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.
   Kim Y, Hammerman PS, Kim J, et al. · J Clin Oncol · 2014 · Background
   PubMed: PMID 24323028 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
3. CD74-NRG1 fusions in lung adenocarcinoma.
   Fernandez-Cuesta L, Plenker D, Osada H, et al. · Cancer Discov · 2014 · Background
   PubMed: PMID 24469108 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
4. Comprehensive molecular profiling of lung adenocarcinoma.
   Cancer Genome Atlas Research Network · Nature · 2014 · Background
   PubMed: PMID 25079552 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2013 (2 papers)

1. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
   Yu HA, Sima CS, Huang J, et al. · J Thorac Oncol · 2013 · Background
   PubMed: PMID 23407558 · NCT04970693 · Carcinoma, Non-Small-Cell Lung
2. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
   Weickhardt AJ, Scheier B, Burke JM, et al. · J Thorac Oncol · 2013 · Background
   PubMed: PMID 23154552 · NCT04970693 · Carcinoma, Non-Small-Cell Lung

2012 (1 paper)

1. Comprehensive genomic characterization of squamous cell lung cancers.
   Cancer Genome Atlas Research Network · Nature · 2012 · Background
   PubMed: PMID 22960745 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2011 (1 paper)

1. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
   Lee SY, Kim MJ, Jin G, et al. · J Thorac Oncol · 2011 · Background
   PubMed: PMID 20881644 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2010 (1 paper)

1. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
   Wang Q, Wang H, Li P, et al. · Am J Med Sci · 2010 · Background
   PubMed: PMID 20601859 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2009 (2 papers)

1. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
   Herbst RS, Sandler A · Oncologist · 2009 · Background
   PubMed: PMID 18997180 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Molecular predictive and prognostic markers in non-small-cell lung cancer.
   Coate LE, John T, Tsao MS, et al. · Lancet Oncol · 2009 · Background
   PubMed: PMID 19796752 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2008 (6 papers)

1. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
   Pignon JP, Tribodet H, Scagliotti GV, et al. · J Clin Oncol · 2008 · Background
   PubMed: PMID 18506026 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Structure and clinical relevance of the epidermal growth factor receptor in human cancer.
   Kumar A, Petri ET, Halmos B, et al. · J Clin Oncol · 2008 · Background
   PubMed: PMID 18375904 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
3. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
   Kappers I, Klomp HM, Burgers JA, et al. · J Clin Oncol · 2008 · Background
   PubMed: PMID 18757336 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
4. Lung cancer.
   Herbst RS, Heymach JV, Lippman SM, et al. · N Engl J Med · 2008 · Background
   PubMed: PMID 18815398 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
5. The role of the EGFR signaling in tumor microenvironment.
   De Luca A, Carotenuto A, Rachiglio A, et al. · J Cell Physiol · 2008 · Background
   PubMed: PMID 17894407 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
6. EGFR antagonists in cancer treatment.
   Ciardiello F, Tortora G · N Engl J Med · 2008 · Background
   PubMed: PMID 18337605 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2007 (2 papers)

1. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
   Yun CH, Boggon TJ, Li Y, et al. · Cancer Cell · 2007 · Background
   PubMed: PMID 17349580 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
   Jimeno A, Hidalgo M · Biochim Biophys Acta · 2007 · Background
   PubMed: PMID 17045403 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2006 (1 paper)

1. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
   Sandler A, Gray R, Perry MC, et al. · N Engl J Med · 2006 · Background
   PubMed: PMID 17167137 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2005 (1 paper)

1. Oncogenic growth factor receptors: implications for signal transduction therapy.
   Mosesson Y, Yarden Y · Semin Cancer Biol · 2005 · Background
   PubMed: PMID 15219619 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2002 (1 paper)

1. Cancer. Addiction to oncogenes--the Achilles heal of cancer.
   Weinstein IB · Science · 2002 · Background
   PubMed: PMID 12098689 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

2001 (2 papers)

1. Untangling the ErbB signalling network.
   Yarden Y, Sliwkowski MX · Nat Rev Mol Cell Biol · 2001 · Background
   PubMed: PMID 11252954 · NCT05987826 · Carcinoma, Non-Small-Cell Lung
2. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
   Ellerbroek SM, Halbleib JM, Benavidez M, et al. · Cancer Res · 2001 · Background
   PubMed: PMID 11280738 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

1999 (1 paper)

1. The epidermal growth factor receptor and its inhibition in cancer therapy.
   Woodburn JR · Pharmacol Ther · 1999 · Background
   PubMed: PMID 10454201 · NCT05987826 · Carcinoma, Non-Small-Cell Lung

1998 (1 paper)

1. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton.
   Hazan RB, Norton L · J Biol Chem · 1998 · Background
   PubMed: PMID 9535896 · NCT05987826 · Carcinoma, Non-Small-Cell Lung